Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $71.255 million which beat the analyst consensus estimate of $67.277 million by 5.91 percent. This is a 46.91 percent increase over sales of $48.502 million the same period last year.